Dianthus Therapeutics, Inc. /DE/
Close on Oct 19, 2026
- Market cap
- $4.18B
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Earnings
Next report expected Oct 15, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 4, 2026 | During market hours | $761.00K | $-0.90 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | During market hours | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 12, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 16, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | During market hours | $193.00K | $-0.88 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | During market hours | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 11, 2025 | During market hours | $1.33M | $-0.81 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | During market hours | $2.17M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 21, 2024 | During market hours | – | – | – |
Press releases
Announcements Dianthus Therapeutics filed with the SEC
DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS
Results of operations · EX-99.1 to Form 8-K
Advancing a leading autoimmune-focused company June 2026 Exhibit 99.1
Other events · EX-99.1 to Form 8-K
DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS
Results of operations · EX-99.1 to Form 8-K
Advancing a leading autoimmune-focused company March 2026 Exhibit 99.1
Other events · EX-99.1 to Form 8-K
DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS, INCLUDING GO DECISION FOR PHASE 3 CAPTIVATE CIDP TRIAL,
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
DIANTHUS THERAPEUTICS ANNOUNCES EARLY GO DECISION FOLLOWING INTERIM RESPONDER ANALYSIS IN PHASE 3 CAPTIVATE TRIAL OF CLASEPRUBART IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP)
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Dianthus Therapeutics Early GO Decision in CAPTIVATE CIDP Trial March 9, 2026 Exhibit 99.3
Results of operations · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Advancing a leading autoimmune-focused company January 2026 Exhibit 99.1
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS
Results of operations · EX-99.1 to Form 8-K
Corporate Presentation November 2025 Exhibit 99.1
Other events · EX-99.1 to Form 8-K
Dianthus Therapeutics Licensing of DNTH212 (BDCA2 and BAFF/APRIL) from Leads Biolabs October 16, 2025 Exhibit 99.1
Material agreement · Results of operations · Other events · EX-99.1 to Form 8-K
DIANTHUS THERAPEUTICS ANNOUNCES POSITIVE DATA FOR CLASEPRUBART (DNTH103) FROM THE PHASE 2 MAGIC TRIAL IN
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Claseprubart (DNTH103) Top-line Ph. 2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS
Results of operations · EX-99.1 to Form 8-K
DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS
Results of operations · EX-99.1 to Form 8-K
DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS
Results of operations · EX-99.1 to Form 8-K
Corporate Presentation December 2024 Exhibit 99.1
Other events · EX-99.1 to Form 8-K
DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS
Results of operations · EX-99.1 to Form 8-K
DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS
Results of operations · EX-99.1 to Form 8-K
Corporate Presentation June 2024 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS AND REPORTS Q1 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
DIANTHUS THERAPEUTICS HIGHLIGHTS RECENT BUSINESS ACHIEVEMENTS AND REPORTS Q4 AND FY2023 FINANCIAL RESULTS
Results of operations · EX-99.1 to Form 8-K
Dianthus Therapeutics Announces $230 Million Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation January 2024 Exhibit 99.1
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Years ended December 31, 2022 and 2021
Other events · EX-99.1 to Form 8-K
Dianthus Therapeutics Highlights Recent Business Achievements and Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Investing in Dianthus Therapeutics, Inc., or Dianthus, securities involves a high degree of risk. You should carefully consider the risk
Results of operations · Executive or director change · Other events · EX-99.1 to Form 8-K/A
shall have the meanings ascribed to them in Dianthus definitive proxy statement/prospectus filed with the U.S. Securities and Exchange Commission on August 1, 2023.
Results of operations · Executive or director change · Other events · EX-99.2 to Form 8-K/A
DIANTHUS MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Results of operations · Executive or director change · Other events · EX-99.3 to Form 8-K/A
Magenta Therapeutics Announces Completion of Merger with Dianthus Therapeutics and Implementation of Reverse Stock Split
Material agreement · Acquisition or disposition completed · Unregistered share sale · Auditor change · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Agenda | Merger Announcement Introductions & Steve Mahoney,
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.2 to Form 8-K
Magenta Therapeutics and Dianthus Therapeutics
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.3 to Form 8-K
Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan
Material agreement · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Magenta Therapeutics to Explore Strategic Alternatives
Listing notice · Regulation FD disclosure · EX-99.1 to Form 8-K
Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2
Regulation FD disclosure · EX-99.1 to Form 8-K